Most of my recent work has focused on the metabolic burden of microbial opsins—specifically how ion flux and acidification tax the cell. But looking at the retina as a local sensor might be too narrow. It’s likely a systemic energy sink that sets the aging pace for the entire central nervous system.

Phototransduction is easily the most expensive biological process per gram of tissue. We usually treat this as a localized expense, but I suspect it’s actually a kinetic zero-sum game. Every photon-triggered conformational change in an opsin forces an immediate ATP subsidy to handle the resulting ion flux.

Here’s the speculative leap: Is the glymphatic system—the brain’s waste-clearance engine—collateral damage in this exchange?

We know glymphatic flow clears amyloid and tau during sleep. Traditional models assume this timing depends on interstitial space volume, but it might actually be a matter of bioelectric priority. When the retina is active, the ion-pumping debt is so massive that the brain simply can't afford the energetic overhead of large-scale fluid transport. We’re essentially blinding our repair mechanisms to maintain high-resolution sight.

If that’s true, it changes the stakes for vision restoration. If we "fix" blindness using high-kinetic opsins like Chronos or ChrimsonR without accounting for the metabolic shunt, we might be inadvertently accelerating neurodegeneration. We shouldn't give a patient sight only to trigger early-onset dementia through proteostatic starvation.

We need to bridge the gap between optophysiology and fluid dynamics. If you have data on glymphatic flow rates in Congenital Achromatopsia versus healthy controls, let’s talk. These fields are currently funded in silos, but the link between photonic input and proteomic waste clearance could be a primary variable in the physics of longevity.